Lopinavir-Ritonavir is a Oral Solution in the Human Prescription Drug category. It is labeled and distributed by Lannett Company, Inc.. The primary component is Lopinavir; Ritonavir.
| Product ID | 0527-1947_38d504a6-4379-49db-b7ce-287a0c716eed |
| NDC | 0527-1947 |
| Product Type | Human Prescription Drug |
| Proprietary Name | Lopinavir-Ritonavir |
| Generic Name | Lopinavir-ritonavir |
| Dosage Form | Solution |
| Route of Administration | ORAL |
| Marketing Start Date | 2016-12-27 |
| Marketing Category | ANDA / ANDA |
| Application Number | ANDA207407 |
| Labeler Name | Lannett Company, Inc. |
| Substance Name | LOPINAVIR; RITONAVIR |
| Active Ingredient Strength | 80 mg/mL; mg/mL |
| Pharm Classes | HIV Protease Inhibitors [MoA],Protease Inhibitor [EPC],P-Glycoprotein Inhibitors [MoA],Cytochrome P450 3A Inhibitors [MoA],Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA],HIV Protease Inhibitors [MoA],Cytochrome P450 3A Inhibitor [EPC],Protease Inhibitor [EPC],Cytochrome P450 3A Inhibitors [MoA],Cytochrome P450 2D6 Inhibitors [MoA],Cytochrome P450 2C19 Inducers [MoA],Cytochrome P450 3A Inducers [MoA],P-Glycoprotein Inhibitors [MoA],Breast Cancer Resistance Protein Inhibitors [MoA],Cytochrome P450 3A4 Inhibitors [MoA],Cytochrome P450 1A2 Inducers [MoA],Cytochrome P450 2C9 Inducers [MoA],Cytochrome P450 2B6 Inducers [MoA],UDP Glucuronosyltransferases Inducers [MoA] |
| NDC Exclude Flag | N |
| Listing Certified Through | 2019-12-31 |
| Marketing Start Date | 2016-12-27 |
| NDC Exclude Flag | N |
| Sample Package? | N |
| Marketing Category | ANDA |
| Application Number | ANDA207407 |
| Product Type | HUMAN PRESCRIPTION DRUG |
| Billing Unit | ML |
| Marketing Start Date | 2016-12-27 |
| Ingredient | Strength |
|---|---|
| LOPINAVIR | 80 mg/mL |
| SPL SET ID: | 4b1caefa-e6a2-42f3-9194-6dc1dd9e6d85 |
| Manufacturer | |
| UNII | |
| RxNorm Concept Unique ID - RxCUI | |
| UPC Code |